Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
University of California, Irvine
City of Hope Medical Center
Jonsson Comprehensive Cancer Center
Children's Oncology Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
Children's Oncology Group
Sarcoma Alliance for Research through Collaboration
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Dana-Farber Cancer Institute
NYU Langone Health
City of Hope Medical Center
National Cancer Institute (NCI)
Children's Oncology Group
City of Hope Medical Center
European Organisation for Research and Treatment of Cancer - EORTC
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
GOG Foundation
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
GOG Foundation
Radiation Therapy Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Duke University
Children's Oncology Group
University of Kentucky
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
OHSU Knight Cancer Institute
Swiss Cancer Institute
Sarcoma Alliance for Research through Collaboration